Zydus Lifesciences Receives USFDA EIR for Ahmedabad Injectable Facility with VAI Classification
Zydus Lifesciences Limited has announced that it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its injectable manufacturing facility located at Zydus Biotech Park, Ahmedabad. The facility has been classified under Voluntary Action Indicated (VAI) following a Good Manufacturing Practices (GMP) surveillance inspection.
The company disclosed the development through a regulatory filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Highlights
- Company: Zydus Lifesciences Limited
- Regulatory Authority: U.S. Food and Drug Administration (USFDA)
- Facility: Injectable manufacturing facility at Zydus Biotech Park, Ahmedabad
- Inspection Type: GMP Surveillance Inspection
- Inspection Period: April 27, 2026, to May 5, 2026
- Outcome: Establishment Inspection Report (EIR) received
- Classification: Voluntary Action Indicated (VAI)
USFDA Inspection Outcome
The USFDA conducted a Good Manufacturing Practices (GMP) surveillance inspection at Zydus Lifesciences’ injectable manufacturing facility in Ahmedabad between April 27 and May 5, 2026.
Following the inspection, the company has now received the Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification, indicating the conclusion of the inspection process.
Regulatory Disclosure
Zydus Lifesciences informed the stock exchanges that the announcement has been made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to disclose material developments that may be relevant to investors.
About the EIR and VAI Classification
An Establishment Inspection Report (EIR) is issued by the USFDA after the completion and review of a facility inspection. A Voluntary Action Indicated (VAI) classification means that while the inspection identified certain observations, they do not warrant regulatory enforcement action. Any corrective measures, if required, are expected to be addressed voluntarily by the company.
The receipt of the EIR marks the successful closure of the USFDA inspection process for Zydus Lifesciences’ Ahmedabad injectable manufacturing facility. Maintaining compliance with global regulatory standards remains important for the company’s pharmaceutical manufacturing operations and supports its continued presence in regulated international markets.